Disease relevance of ST7

• These data suggest that LOH at 7q31-q35 is involved in the origin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target gene of this somatic event [1].
• Subsequent investigation described the presence of ST7 mutations in human cell lines derived from breast tumors and primary colon carcinoma [2].
• To clarify the role of the ST7 gene in cancer, we scrutinized primary head and neck squamous cell carcinomas, invasive ductal carcinomas of the breast, and adenocarcinomas of the colon [2].
• ST7 gene, a candidate tumor suppressor gene identified recently at human chromosome 7q31.1, was also detected because LOH at this site has also been widely reported in stomach cancer [3].
• We, therefore, sought to examine a total of 22 human malignant myeloid tumor cell lines comprising 17 of acute myelogenous leukemia (AML) cell lines and 5 chronic myelogenous leukemia (CML) cell lines for somatic mutations of the ST7 gene by means of bidirectional direct DNA sequencing analysis [4].

High impact information on ST7

• The gene ST7 has been proposed as the multi-tissue tumor-suppressor gene (TSG) at chromosome 7q31 [5].
• Absence of ST7 mutations in tumor-derived cell lines and tumors [5].
• The gene ST7 has recently been implicated as the broad-range tumor suppressor on human chromosome 7q31 [6].
• Mutation of the ST7 tumor suppressor gene on 7q31.1 is rare in breast, ovarian and colorectal cancers [6].
• 1. We did not detect somatic mutations in ST7 in any of 149 primary ovarian, breast or colon carcinomas [6].

Biological context of ST7

• We screened the exons of RAY1/ST7 and ST7OT1-3 for sequence variants in 90 unrelated autism probands and identified several rare variants, including a Ile361Val substitution [7].
• The RAY1/ST7 tumor-suppressor locus on chromosome 7q31 represents a complex multi-transcript system [7].
• Suppressor of tumorigenicity 7 (ST7) has been identified as a candidate tumor suppressor gene in this region [1].
• An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma [1].
• ST7 is a candidate tumour suppressor gene at human chromosome locus 7q31 [8].

Anatomical context of ST7

• Mutational analysis of the ST7 gene in human myeloid tumor cell lines [4].

Associations of ST7 with chemical compounds

• METHODS: Acyclovir and penciclovir IC(50)'s for 12 HSV clinical isolates were measured in two laboratories using plaque reduction assay (PRA), an enzyme immunoassay (EIA)-based antigen reduction, and DNA hybridization on Vero, A549, MRC-5, HEL299 and HELG monolayers [9].

Other interactions of ST7

• We have also identified a third alternative 3' end of RAY1/ST7 that uses exons from ST7OT3 [7].
• ST7OT2 spans from RAY1/ST7 intron 9 to intron 1, and has multiple isoforms [7].
• ST7OT1 overlaps with the RAY1/ST7 exon 1 and promoter [7].
• Seven fragments spanning the 11 exons were used to detect the mutation of p53 gene and the four exons reported to have mutations in ST7 gene were amplified by PCR and directly analyzed by DHPLC without mixing with wild-type allele [3].
• To ascertain the frequency of mutations of the ST7 gene in cancer cells, we examined mutations in the ST7 coding sequence in 48 colorectal, 48 gastric, and 48 hepatocellular carcinomas using polymerase chain reaction-single-strand conformational polymorphism and direct sequencing [10].

Analytical, diagnostic and therapeutic context of ST7

• In addition, quantitative RT-PCR analyses of ST7 mRNA expression levels in 11/13 normal-tumor pairs failed to show more than a 50% decrease in tumor ST7 mRNA relative to matched normal tissues [1].
• Mean ST7 perfusion values were different from L0 and LG1, but only mean relative cerebral blood volume (rCBV) was different from LG7, discriminating survival against death of tissue [11].

References